Daily high-dose aspirin does not lower APRI in the Aspirin-Myocardial Infarction Study
基本信息来源于合作网站,原文需代理用户跳转至来源网站获取
摘要:
Antiplatelet agents reduce liver fibrosis by inhibiting platelet activation and platelet-derived growth factor production.Previous cross-sectional epidemiological studies suggest that the use of aspirin is related to reduced liver fibrosis.The Aspirin-Myocardial Infarction Study (AMIS) aims to examine this relationship in a multicenter,randomized,double-blind and placebo-controlled trial.The existing clinical trial of aspirin was conducted to study the benefit of one gram aspirin daily among 4 524 individuals who had experienced at least one documented myocardial infarction.The aspartate aminotransferase (AST)-to-Platelet Ratio Index (APRI) was calculated at baseline and annually from the platelet count and AST levels.Participants in the AMIS trial had a mean baseline APRI of 0.34±0.36,and only 1% individuals had APRI scores higher than 1.0,a common cutoff for cirrhosis.The daily use of aspirin was associated with an increase,rather than a reduction of APRI,by 0.007 per year (95% CI 0.002-0.015,P=0.12).The use of aspirin did not significantly affect platelet counts.In a sensitivity analysis of individuals with probable significant fibrosis at baseline (APRI≥0.7),the aspirin group had a sustained reduction in APRI over time,although this change was not significant compared to that in the placebo group.In the AMIS trial,the daily use of high-dose aspirin did not significantly affect APRI,a surrogate index of liver fibrosis.This study highlights the need for de novo clinical trials to investigate the potential benefit of antiplatelet agents on liver fibrosis.